Dexcom stock fell Thursday after the diabetes devices maker's second-quarter earnings and revenue topped estimates and the company named a new chief executive officer. The company raised full-year revenue guidance but only by the size of the Q2 beat.
Dexcom reported Q2 earnings after the market close on Wednesday. It named Jake Leach as CEO effective Jan. 1, 2026. He will also join the board of directors.
Current CEO Kevin Sayer will remain executive chairman of the board. In May, Dexcom promoted Leach to president, in addition to his role as chief operating officer.
In the quarter ended June 30, Dexcom earnings came in at an adjusted 48 cents per share, up nearly 12% from a year earlier. Revenue rose 15% to $1.157 billion, including a $6 million gain from currency exchange rates.
2025 Guidance Hiked
Analysts polled by FactSet had projected adjusted EPS of 44 cents on revenue of $1.125 billion.
Dexcom also raised full-year 2025 guidance to a range of $4.6 billion to $4.625 billion.
"Revenue guidance raised to $4.6 billion to $4.625 billion, with the upper end of the range increased by the magnitude of the Q2 beat," said Truist Securities analyst Richard Newitter in a report. "Management outlined increasing Stelo downloads as potential second half growth drivers, though it did not raise the midpoint of full-year guidance by the entire amount Q2 beat. The guidance implies deceleration in second half, which we attribute to management conservatism to ensure the company can deliver ongoing beats as it seeks to get past last year's second half miss and lowering of guidance."
On the stock market today, Dexcom stock fell 4.5% to 85 in early trading. Heading into the Dexcom earnings report, shares had advanced 14% in 2025.
Dexcom Stock Technical Ratings
San Diego, Calif.-based Dexcom makes continuous glucose monitors, or CGMs. These body-worn devices keep tabs on blood sugar in real time, helping patients with diabetes and people who want to know more about their metabolic health.
Dexcom's Stelo product is the company's CGM for patients who don't use insulin.
Further, Dexcom stock holds a Composite Rating of 87 out of a best-possible 99, according to IBD Stock Checkup.
Meanwhile, Dexcom stock holds an Accumulation/Distribution Rating of B-minus. That rating analyzes price and volume changes in a stock over the past 13 weeks of trading. (A+ signifies heavy institutional buying; E means heavy selling. Think of a C grade as neutral.)
Follow Reinhardt Krause on X, formerly Twitter, @reinhardtk_tech for updates on artificial intelligence, cybersecurity and cloud computing.
